ArticleFrontiers in endocrinology2025
Atherogenic index of plasma and cardiovascular disease risk in cardiovascular-kidney-metabolic syndrome stage 1 to 3: a longitudinal study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Association between the atherogenic index of plasma and prognosis in kidney transplant recipients: a retrospective cohort study.International urology and nephrology · 2026Article
- Insulin Resistance and Atherogenic Dyslipidemia Drive Cardiac Remodeling and Cardiovascular Events After Kidney Transplantation.Journal of clinical medicine · 2026Article
- Longitudinal cohort study on the dynamic changes of atherogenic index of plasma and the risk of cardiometabolic multimorbidity in middle - aged and elderly people.BMC cardiovascular disorders · 2026Article
- Association between the cumulative atherogenic index of plasma and cardiometabolic multimorbidity: the mediating effects of the TyG index and body mass index.Lipids in health and disease · 2026Article
- Developing and evaluating machine learning-based risk models for metabolic syndrome among nurses: a cross-sectional study.Frontiers in public health · 2026Article
- HbA1c-to-HDL-C ratio and risk of incident cardiovascular disease among older adults: evidence from a 7-year prospective cohort study in southwestern China.Frontiers in public health · 2026Article
- Predicting Stroke Incidence Using Estimated Glucose Disposal Rate Index in the Population with Cardiovascular-Kidney-Metabolic Syndrome Stage 0-3 in the Chinese Middle-Aged and Elderly Population.Cardiorenal medicine · 2026Observational
- Editorial: Novel strategies for the clinical management of cardiovascular-kidney-metabolic syndrome.Frontiers in endocrinology · 2026Article
- Impacts of Herbal Medicine Use on Lipid Profiles in Type 2 Diabetic Patients in Northwest Ethiopia: A Comparative Cross-Sectional Study.BioMed research international · 2026Article
- Developments in the Management Strategies for Allergy: Advances in Artificial Intelligence and Future Perspectives.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2026Review
- Neutrophil percentage to albumin ratio and advanced cardiovascular-kidney-metabolic syndrome in diabetes: a machine learning approach.European journal of medical research · 2025Article
- Incorporation of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Health Stage of Cardiovascular-Kidney-Metabolic Syndrome Improves Predictive Ability for Coronary Artery Disease in a Japanese General Population.Journal of the American Heart Association · 2025Article
- Cardiovascular-Kidney-Metabolic Syndrome: A New Paradigm in Clinical Medicine or Going Back to Basics?Journal of clinical medicine · 2025Review
- Association between atherogenic index of plasma and future cardiovascular disease risk in middle-aged and elderly individuals with cardiovascular-kidney-metabolic syndrome stage 0-3.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease (CVD) remains a major contributor to the global disease burden. Previous studies have established a link between the atherogenic index of plasma (AIP) and CVD. However, it remains unclear whether cumulative AIP and AIP control influence the future incidence of CVD in individuals with Cardiovascular-Kidney-Metabolic (CKM) syndrome. This study aims to explore the association between cumulative AIP, AIP control levels, and the risk of CVD in individuals with CKM syndrome from stages 1 to 3. Methods: Participants with CKM syndrome were drawn from the China Health and Retirement Longitudinal Study (CHARLS). Cumulative AIP was calculated using triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C), while AIP control levels were categorized into four groups via k-means clustering. CVD was defined by self-reported heart disease or stroke. Multivariable logistic regression and restricted cubic spline analysis were employed to examine the association between AIP and incident CVD in individuals with CKM syndrome. Results: A total of 793 participants (18.84%) developed CVD. After adjusting for confounders, cumulative AIP were associated with the developing CVD (OR=1.139, 95% CI: 1.017-1.275, P=0.0245). Compared to group 1 (best AIP control), the OR (95% CI) for incident CVD were 1.278 (0.959-1.702) for group 2, 1.329 (1.076-1.641) for group 3, and 1.195 (0.974-1.465) for group 4. Restricted cubic spline regression indicated the relationship between cumulative AIP and CVD risk is linear (P for nonlinear = 0.3377). Conclusions: In middle-aged and elderly individuals with CKM syndrome, higher cumulative AIP and poorer AIP control were associated with an elevated incidence of CVD. These findings suggest that enhanced assessment of the AIP index could inform targeted prevention strategies for CVD in the context of CKM syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.